(Q35183734)

7 August 2017

1 reference

title

The lipid formulations of amphotericin B. (English)

1 reference

7 August 2017

4

Valérie Letscher-Bru

1 reference

7 August 2017

2

Shanti Natarajan-Amé

1 reference

7 August 2017

3

Yasmine Nivoix

1 reference

7 August 2017

1

Raoul Herbrecht

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Expert Opinion on Pharmacotherapy

7 August 2017

published in

1 reference

7 August 2017

volume

4

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

1277-1287

1 reference

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Safety of amphotericin B colloidal dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Amphotericin B lipid complex therapy of experimental fungal infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Lipid formulations of amphotericin B: clinical efficacy and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Clinical use of liposomal and lipid-complexed amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Liposomal amphotericin B for fever and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Renal effects of amphotericin B lipid complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

Antifungal pharmacotherapy for invasive mould infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1277

10.1517/14656566.4.8.1277

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference